Despite a revenue dip, investors bank on Repligen's future growth, justifying a high P/S ratio. Strong revenue forecasts may keep share prices up, unless analysts' predictions are off.
No recent insider transactions at Repligen isn't concerning, but last year's transactions aren't encouraging. Modest insider ownership suggests alignment with shareholders. However, Repligen has 1 warning sign that shouldn't be ignored.
The growth of Repligen parallels investors' sentiment, with EPS growth and yearly share price increases closely matched. Five-year return of 30% suggests consolidation amidst the firm's continued execution of its growth strategy.
Repligen's projected profit growth and evident undervaluation signal a good investment opportunity. The unreflected potential in the share price suggests now is a desirable time to buy.
Pre-Market Stock Movers Gapping up $Meta Platforms (META.US)$+0.81% (The social media gianted in premarket trading after the launch of Threads, a direct competitor to Twitter. Meta CEO Mark Zuckerberg said on his Threads account early Thursday that 10 million people had signed up for the platform in seven hours after launching.) $Sweetgreen (SG.US)$+5.14% (Sweetgreen jumped more than 4% after Bank of America upgraded...
Brief thoughts on why I added to each: - Netflix - I always wanted to buy but never liked the price. Now with its 50-day MA set to pass its 200, I figure I might as well jinx it with my minimal TA knowledge. - Crox - Declining ROIC, but still at 24% in its last quarter, even bringing HEYDUDE into the fold. - Repligen - Picks and shovels play to the biotech industry, and I want to increase my exposure there. $Netflix (NFLX.US)$$Crocs (CROX.US)$$Repligen (RGEN.US)$$Disney (DIS.US)$
$Repligen (RGEN.US)$ Can keep this one in watchlist for next week. Interesting price action. Price already up after earnings yet a flush down. Volume were high but still managed to close green above key lvl. A tell tale for hunting SL. A gd entry will be 257.50. SL will be -1% from there. (If price does drop to 257.50, see if it cut under first, enter after rebound lest it hit your -1%). As long price stay below that lvl, setup is void
2
1
Report
Mett
OP
:
Doubt it’s coming down to 257.50. Will watch and give it a shot if it gaps up at open. SL at LOD
$Accenture (ACN.US)$Accenture (ACN) target raised by Barclays from $335 to $384 at Overweight. Stock currently around $335 $AstraZeneca (AZN.US)$AstraZeneca (AZN) target raised by SVB Leerink from $71 to $73 at Outperform. Stock currently around $59 $Best Buy (BBY.US)$Best Buy (BBY) target raised by Piper Sandler from form $146 to $150 at Overweight. Stock currently around $110 $Costco (COST.US)$Costco (COST) target raised by Credit Suisse from $400 to $490 at Neutral. Stock currently around $460 $Repligen (RGEN.US)$rgenRepligen (RGEN) target raised by Craig Hallum from $258 to $368 at Buy. Stock currently around $305
10
Report
No comment yet
- No more -
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Repligen Stock Forum
Gapping up
$Meta Platforms (META.US)$ +0.81% (The social media gianted in premarket trading after the launch of Threads, a direct competitor to Twitter. Meta CEO Mark Zuckerberg said on his Threads account early Thursday that 10 million people had signed up for the platform in seven hours after launching.)
$Sweetgreen (SG.US)$ +5.14% (Sweetgreen jumped more than 4% after Bank of America upgraded...
Gap Ups
1. $PLDT (PHI.US)$ - up 2.6%
2. $Avis Budget (CAR.US)$ - up 2.2%
3. $Bank Bradesco SA(prefer share ADS) (BBD.US)$ - up 0.8%
4. $Sanofi (SNY.US)$ - up 0.7%
5. $Grifols (GRFS.US)$ - up 0.4%
6. $Lumentum (LITE.US)$ - up 0.3%
Gap Downs
1. $Bilibili (BILI.US)$ - down 4.0%
2. $Olin (OLN.US)$ - ...
Gap Ups
1. $Teck Resources (TECK.US)$ - up 10.6%
2. $Apellis Pharmaceuticals (APLS.US)$ - up 9.5%
3. $Apache (APA.US)$ - up 5.8%
4. $Schlumberger (SLB.US)$ - up 5.0%
5. $TotalEnergies (TTE.US)$ - up 4.9%
6. $Shell (SHEL.US)$ - up 3.8%
7. $BP PLC (BP.US)$ - up 3.7%
8. $Transocean (RIG.US)$ ...
- Netflix - I always wanted to buy but never liked the price. Now with its 50-day MA set to pass its 200, I figure I might as well jinx it with my minimal TA knowledge.
- Crox - Declining ROIC, but still at 24% in its last quarter, even bringing HEYDUDE into the fold.
- Repligen - Picks and shovels play to the biotech industry, and I want to increase my exposure there.
$Netflix (NFLX.US)$ $Crocs (CROX.US)$ $Repligen (RGEN.US)$ $Disney (DIS.US)$
Can keep this one in watchlist for next week. Interesting price action. Price already up after earnings yet a flush down. Volume were high but still managed to close green above key lvl. A tell tale for hunting SL. A gd entry will be 257.50. SL will be -1% from there. (If price does drop to 257.50, see if it cut under first, enter after rebound lest it hit your -1%). As long price stay below that lvl, setup is void
$AstraZeneca (AZN.US)$ AstraZeneca (AZN) target raised by SVB Leerink from $71 to $73 at Outperform. Stock currently around $59
$Best Buy (BBY.US)$ Best Buy (BBY) target raised by Piper Sandler from form $146 to $150 at Overweight. Stock currently around $110
$Costco (COST.US)$ Costco (COST) target raised by Credit Suisse from $400 to $490 at Neutral. Stock currently around $460
$Repligen (RGEN.US)$ rgenRepligen (RGEN) target raised by Craig Hallum from $258 to $368 at Buy. Stock currently around $305
No comment yet